Dyadic International (NASDAQ:DYAI) Share Price Passes Above 50-Day Moving Average – What’s Next?

Dyadic International Inc. (NASDAQ:DYAI) shares passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.94 and traded as high as $1.1550. Dyadic International shares last traded at $1.08, with a volume of 83,162 shares changing hands.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dyadic International in a research note on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Dyadic International has a consensus rating of “Hold” and a consensus target price of $3.00.

Dyadic International Stock Performance

The company has a debt-to-equity ratio of 4.08, a quick ratio of 2.42 and a current ratio of 2.42. The firm has a market cap of $39.36 million, a P/E ratio of -4.70 and a beta of 1.12. The company’s 50 day moving average is $0.94 and its 200 day moving average is $0.86.

Dyadic International (NASDAQ:DYAI) last posted its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). The company had revenue of $1.11 million for the quarter, compared to the consensus estimate of $0.90 million. Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%. As a group, equities analysts predict that Dyadic International Inc. will post 0.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dyadic International

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Landscape Capital Management L.L.C. acquired a new position in Dyadic International in the 3rd quarter worth about $190,000. Marathon Capital Management boosted its stake in shares of Dyadic International by 142.9% during the fourth quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 50,000 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Dyadic International by 13.7% during the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 36,266 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 26,965 shares during the last quarter. Institutional investors own 27.95% of the company’s stock.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.